Treatment of Inflammatory Bowel Disease with Biologics

Adam S. Cheifetz, MDBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USAJoseph D. Feuerstein, MDBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

• Mechanism of Action and Pharmacokinetics of Biologics.- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis.- Anti-tumor Necrosis Factor Agents in Crohn’s Disease.- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease.- Use of Biologics in the Postoperative Management of Crohn’s Disease.- Biologics in Pregnancy and Breastfeeding.- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease.- Therapeutic Drug Monitoring of Biologic Agents.- Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks.- Cessation of Biologics – Can it be Done?.- Biologic Therapy in Pediatric Inflammatory Bowel Disease.- Infectious Complications of Biologics.- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy.- Non-infectious and Non-malignant Complications of Biologics.- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances.- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications.- Novel Agents in Inflammatory Bowel Disease.- Quality, Safety, and Practical Considerations of Using Biologic Therapies.